A next generation of AMR diagnostics
AI-guided antibiotic-resistance diagnostics, personalised to the patient's microbiome — running on the PCR platforms hospitals already own.
Resistance testing ignores the patient's microbiome — which reshapes both the bacterial community and how drugs work. The result is mistreatment, at massive human and economic cost.
We're building a microbiome-personalised AMR diagnostic test — currently in development — that runs on the PCR instruments hospitals already operate, and returns a susceptible / resistant call through the lab's own systems.
A patient sample, collected with preservative.
Multiplex PCR across a panel of resistance targets.
QR-linked to the patient, tracked through the workflow.
A resistance result delivered to clinicians in under 2h.
Personalised to the patient's microbiome · validated on 5,000+ genomes · no new instruments required.
Antibiotic resistance is multi-causal, so we combine genomics, microbiome science and AI into a single engine for discovering and calling resistance.
Calls drug resistance directly from whole-genome sequencing data.
Profiles the gut and oral microbiome and links its signatures to clinical outcomes.
A cross-species model that predicts resistance — and shows the reasoning behind every call.
Selected journals featuring peer-reviewed work by the Gigabiome founding team.
A founding team spanning computational biology, microbiome science and world-leading clinical medicine.
Bioinformatics and systems biology (King's College London, Francis Crick Institute).
Internationally recognised microbiome scientist at King's College London and founder of several biotech companies.
UCL Professor of Hepatology, 500+ published articles, and founder of three clinical-stage biotech companies.
For partnership, clinical collaboration or investor enquiries, we'd like to hear from you.
Email the team
